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Nature provides abundant examples of protein families with highly diverged sequences. The ability to              
design new protein homologs has many applications, yet synthetic approaches have been unable to              
generate similarly diverse protein sequences with functional activity in the lab [1, 2]. New technologies               
offer a solution: high-throughput DNA synthesis and sequencing technologies allow thousands of            
designed sequences to be assayed in parallel, enabling deep diversification guided by machine learning              
(ML) models that relate protein sequence to function without detailed biophysical or mechanistic             
modeling. Here we apply deep learning to design novel adeno-associated virus (AAV) capsid proteins, a               
challenging target of great utility for gene therapy. Focusing on a 28-amino acid segment spanning buried                
and exposed regions, we generated 201,426 highly diverse variants of the AAV2 wildtype (WT)              
sequence, yielding 110,689 viable synthetic capsids, 57,348 of which surpass the average diversity of              
natural AAV serotype sequences with 12-29 mutations across this region. Even when trained on limited               
data, deep neural network models accurately predicted capsid viability across highly diverse variants.             
Deep diversification enables the design of AAV capsids with completely synthetic sequences for the              
universal treatment of all patients regardless of prior exposure to natural AAV, while demonstrating a               





Engineering protein phenotypes is limited by our ability to mutate multiple positions in a protein sequence                
and predict the functional outcome. Despite outstanding progress in computational de novo protein design              
[3-5], simulation based predictions are challenging for large natural protein complexes. Moreover,            
biophysical models falter when modifications affect conformation, since the physical interactions that            
determine protein function are not well understood [6-8]. Directed evolution is a powerful approach [9-11],               
with the repeated application of random mutation and artificial selection often being the default              
engineering strategy when mechanistic understanding is limited, as is the case for proteins like AAV               
capsids [12, 13​]​. Recent high-throughput DNA sequencing-based assays allow large-scale mapping of            
fitness landscapes [14-16], while advances in DNA synthesis and ML technologies enable a completely              
data-driven workflow for accelerated directed evolution [2, 17-23]. However, it is unknown to what extent               
ML models trained on and around natural sequences can generate functional sequences substantially             
different from any natural homolog. We applied ML-guided diversification to the AAV capsid, a complex               
multi-protein assembly, as a case study to test whether data collected from high-throughput experiments              
can yield ML models that successfully guide the design of functional and diverse sequence variants. We                
validated our approach with a massively parallel experimental study to directly test the utility of machine                
learning for biological sequence design and diversification (Fig 1a). 
 
AAV capsids hold tremendous promise as gene delivery vectors. The AAV2 capsid is a component of the                 
first gene therapy to receive approval for sale by the U.S. Food and Drug Administration for use in                  
humans [24, 25], while other serotypes are in clinical trials [26]. A major challenge is that immunity due to                   
prior AAV exposure excludes 20-80% of the population from systemically administered therapies            
employing natural capsids [​27​]. Novel and diverse AAV vectors that retain the ability to package DNA                
payloads and transduce cells while evading the humoral immune system are urgently required [28].              
Previous engineering strategies, such as targeted random peptide insertions, error-prone mutagenesis           
[13], random shuffling between AAV serotypes to create chimeric capsids [12], and random mutation at               
structurally-guided positions [29], have had limited success at overcoming antibody neutralization           
because the resultant sequences remain quite similar to natural isolates. Epitopes for neutralizing             
antibodies occur at many locations across the capsid surface [30], indicating that capsids capable of               
avoiding neutralizing serum will require changes to many positions, most likely approaching or exceeding              
the diversity of natural serotypes (i.e. on the order of hundreds of sequence differences). To evaluate the                 
utility of a purely data-driven approach to diversification, we directly generated synthetic sequences near              
the 3-fold symmetry axis of the icosahedral AAV2 capsid protein. Specifically, we targeted positions              
561-588, a region that encompasses buried, surface and interface regions, and overlaps known             
heparin-binding as well as antibody binding sites [30].  
 
Capsid production represents a bottleneck in the creation of diverse AAV capsids as the majority of                
sequence variants fail to assemble or to package their genome [21, 29, 31]. To generate large and                 
diverse datasets for training machine learning models of capsid production, we employed two strategies –               
choosing multi-mutants randomly or based on predictions from simple additive models. For the latter, we               
first assayed all single amino acid substitutions and insertions within the target region (Fig 1b), finding that                 
58% were viable (i.e. assemble an integral capsid that packages the genome). In contrast, randomly               
chosen multi-mutant sequence variants with between 2 and 10 mutations (Levenshtein distance) were             
just 10% viable, with only 0.3% viability for variants with >6 mutations (3 of 1,154). The yield of viable                   
multi-mutants was improved by stochastically sampling from additive models fit on single site data              
 
 
(Methods) to design 56,372 variants with between 2 and 39 mutations in the target region, with the goal of                   
testing the limits of exploration made possible given our prior data: 62.5% were viable, although none of                 
the 1,790 variants with >21 mutations were viable.  
 
To assess different protocols for ML-guided sequence design we examined the impact of (i) training set                
design and (ii) ML model architecture. We compared three ML training datasets designed via Complete               
(C), Random (R) or Additive (A) sampling strategies, splitting data from the prior experiment into three                
sets that vary in the number of sequence variants and their distribution and distance from WT. These                 
splits enable assessment of how training data structure affected model performance (Fig 1b). The              
smallest dataset, C​1​+R​2​, contains the complete set (C​1​) of 1,112 possible single variants plus 1,756               
randomly chosen sequence variants with 2 mutations. The C​1​+R​10 dataset contains C​1 ​together with R​10​,               
7,908 randomly chosen sequence variants with 2-10 mutations, while the R​10​+A​39 dataset contains R​10              
plus the 56,372 additive model-designed sequence variants with 2-39 mutations described above. A fixed              
set of 1,977 randomly chosen sequence variants with 2-10 mutations was held out for hyper-parameter               
tuning (Methods). To avoid overfitting to experimental noise, rather than predicting the quantitative             
production efficiency we used binary classification models to predict whether each sequence variant is              
viable or not (Supplementary Fig 1), as defined by a threshold fit to best separate positive and negative                  
controls (WT replicas and variants containing stop codons respectively).  
 
 
Figure 1 | Generation of diverse sequence variants guided by machine learning models trained on               
deep mutational libraries. a​, ​Experimental workflow: Multiplexed measurement of viability for AAV            
capsid production. Three experiments (helix marker) were conducted to generate production data for: (i)              
all single mutants, (ii) ML training data, and (iii) ML validation data. ​b​, ​ML model training workflow​:                 
Experimental data from mutants generated by complete (C), Random (R) or Additive model (A) design               
 
 
strategies were assembled into three training data sets: C​1​+R​2​, C​1​+R​10​, R​10​+A​39​. Subscripts indicate the              
maximum number of mutations relative to WT. Each data set was used to train three machine learning                 
models with varying architectures and increasing numbers of parameters: Logistic regression (LR),            
Convolutional Neural Network (CNN), Recurrent Neural Network (RNN). ​c​, ​Sequence design workflow​:            
Randomly generated candidates were ranked by model ensemble score to yield model-selected            
sequences. Top candidates were subject to 20 iterative design cycles to obtain model-designed             
sequences. 
 
Across each training set, we compared the performance of three model architectures: a simple logistic               
regression (LR) model, convolutional neural networks (CNNs) and recurrent neural networks (RNNs). ​For             
each of the nine resulting dataset-architecture combinations we trained an ensemble of 11 randomly              
initialized replica models, and used the mean model score from each ensemble to rank 2.1 billion                
sequences (Fig. 1c), corresponding to 100 million sequences sampled uniformly at random at each              
distance from 5 to 25 steps from WT. ​For each ensemble, the 1,000 highest scoring sequences at each                  
distance were chosen as ‘model-selected’ seed sequences. However, in our random training dataset R​10              
the proportion of viable capsid sequences drops rapidly as the distance from WT increases. Toward the                
goal of deep diversification, we therefore used the model ensembles to improve the model selected seed                
sequences. Briefly, to generate ‘model-designed’ variants (Fig 1c), we used the model ensembles to              
iteratively rank, filter, and mutate (via single residue edits) seed sequences for up to 20 rounds (Methods). 
 
For each dataset-architecture combination, the highest scoring model-selected and model-designed          
sequences at each distance 5-29 from WT were synthesized and a total of 201,426 sequence variants                
were experimentally evaluated (Supplementary Tables 1-7). To verify reproducibility between the training            
and validation experiments we re-tested 2000 sequences from the training set as controls, demonstrating              
strong experimental reproducibility (R=0.89, p<10^-20, Supplementary Fig 2).  
 
Figure 2 | ​Experimental validation of synthetic sequences demonstrates high performance and            
robustness of NN models to training data composition. ​a, Performance of model-selected sequences.             
On each plot, black is the randomly generated baseline (N=10,997), gray is the additive baseline               
(N=56,372). Vertical lines show the number of mutations within natural AAV serotypes in the target region                
on average (μ=12), plus additional standard deviations (σ=6). ​b, Performance of model-designed            
sequences. Colored numbers are viable capsids with at least the indicated number of mutations.              




Model-guided design was dramatically successful at generating diverse viable sequence variants. Within            
this region, diverse natural AAV serotypes differ from AAV2 on average at μ=12±6 positions.              
Model-selected sequences from CNN and RNN models had close to 100% viability at 6 mutations from                
WT (Fig 2a), the threshold at which randomly chosen sequence variants were largely non-viable.              
However model-selected viability dropped quickly beyond 12 mutations from WT, most likely because the              
randomly generated candidate sequences that the models had to choose from were overwhelmingly             
non-viable. In contrast, many model-designed sequences with >12 mutations from WT were viable (Fig              
2b). Overall 58.1% of model-designed sequences (​106,665 in total) formed viable capsids with up to 29                
mutations from the WT sequence, including variants with up to 19 substitutions or 15 insertions within the                 
28-residue target segment. On average, the NN model-designed sequences were 33 times more likely to               
be viable than sequences designed by the additive model at 18 mutations (μ+σ) from WT, with even                 
greater improvements at larger distances.  
 
The performance of neural network models was robust to variations in the amount and composition of                
training data. While the LR model trained with the medium sized C​1​+R​10 ​dataset was >90% viable as far                  
as 24 mutations (μ+2σ) from WT, LR models trained on the smallest C​1​+R​2 ​and largest R​10​+A​39 datasets                 
were unreliable (Fig 2b). In contrast, CNN and RNN models trained on the smallest C​1​+R​2 dataset                
successfully designed many variants with >18 mutations (μ+σ) from WT, comparable to those trained on               
the ~3x larger C​1​+R​10 ​and ~22x larger R​10​+A​39 ​datasets (Fig 2b). We note that all models benefitted from                  
the decision to use ensembles (Supplementary Fig. 3). Across all models, and the LR models most                
markedly, we observe that more training data does not guarantee better model performance. To better               




Figure 3 | Neural network models generated greater diversity across positions. a, 3D structure of               
the 28-residue region with boxed buried (purple) and interface regions (pink) colored by residue surface               
accessibility (RSA) for a single monomer, shown in context with interfacing monomers. Average tolerance              
to single substitutions and insertions (measured experimentally) shown for each position along with the              
perplexity and natural diversity across 12 common serotypes (logo plots made with [32]). ​b​, Top:               
Heatmaps showing successful substitutions within viable capsids (≥12 mutations) as designed by each             
model trained on each dataset. WT residues (dots) are masked. Bottom: Mean number of residue type                
substitutions incorporated by position (PP=perplexity).  
 
Models differed in the levels of sequence diversity that they generated. The first 2/3 of the target region is                   
more conserved across natural AAV sequences, likely because these positions are less surface exposed,              
and constrained by the oligomeric interface (Fig 3a). While the performance of models trained on the                
C​1​+R​10 dataset was uniformly high, NN models successfully incorporated diverse residue substitutions at             
buried and interface sites much more frequently than the LR model (Fig 3b, Supplementary Fig 4).                
Additionally, NN models successfully incorporated many insertions into the buried part of the capsid,              
which is intolerant of insertions in general (Fig 3b). While the LR{C​1​+R​10​} model had strong preferences                
for particular amino acids at each position (as seen by its low perplexity in Fig 3b), RNN models exhibited                   
preference for substituting amino-acids with similar chemical properties, while the CNN models tended to              
be more selective among positions (Fig 3b). Moreover, while all models were capable of mutating the                
later, surface accessible portion of the target region, NN models incorporated a greater diversity of amino                
acids at these positions (Fig 3b). The LR{R​10​+A​39​} model exhibited greater diversity (Fig 3b) but relatively                
poor precision (Fig 2b), indicating the importance of sequence context when mutating to more diverse               
sets of amino acids at each position. Conversely, while the LR{C​1​+R​10​} model had the highest precision of                 
all models, the greater per-position diversity of the NN models suggested that their sequence proposals               
were distributed across a much larger region of sequence space. 
 
To test this hypothesis, we quantified model diversity by calculating the number of clusters obtained when                
the viable sequences designed by each model were clustered using pairwise Levenshtein (edit) distance              
(Methods) [33]. For all datasets, CNN and RNN models identified viable sequences covering much larger               
volumes of sequence space than the LR models (Fig 4a). The LR model with highest performance                
(C​1​+R​10​) was also the least diverse, primarily generating highly similar viable sequences. Pure             
maximization of precision or diversity can result in a tradeoff: picking only the highest scoring sequence                
may be precise, but has no diversity, whereas randomly generated sequences have high diversity but low                
precision. Of course, models can also have low diversity and low precision (e.g. in LR{C​1​+R​2​}).  
 
To quantitatively evaluate model performance in this respect, we partitioned all designed sequences into              
clusters of radii 12 edits (μ), and computed the average viability within the resulting clusters. NN models                 
outperformed LR models at all viability thresholds. The RNN performed best for the smallest C​1​+R​2               
dataset, while the CNN performed better for the larger datasets (Fig 4b). Projecting viable sequences               
from the C​1​+R​10 models into 2D with ivis [34] provides visual intuition: The CNN model generated viable                 
capsids across much larger regions of sequence space than the highly accurate LR{C​1​+R​10​} model,              
though we note that all models discovered viable sequence variants that are highly distinct from natural                
AAV serotypes (Fig 4C, Supplementary Fig. 4b-d). In summary, our CNN and RNN design strategies               
were more successful at deep diversification than LR at all precision levels and across all data sets,                 
although better strategies are certainly possible and additional work will determine how these findings              




The success of these diversification strategies (i) addresses the immediate need for synthetic AAV              
capsids with sequences distinct from natural isolates, and (ii) demonstrates that data-driven models can              
perform well on complex proteins without incorporating extensive domain knowledge or physical models,             
even with limited training data (as shown here by the success of models trained using <3000 data points).                  
For AAV, the diverse set of viable sequence variants discovered by the NN models are promising                
candidates to test for additional gain-of-function phenotypes, such as improved cell tropisms and             
manufacturability. More generally, models can be trained to simultaneously predict multiple phenotypes to             
jointly optimize variants for several desirable properties, a task that is significantly more challenging for               
traditional methods of directed evolution.  
 
Figure 4 | Neural networks generated greater functional diversity at equivalent levels of             
performance relative to additive and LR models. Inset​: method for sequence clustering. ​a​, Number of               
distinct viable sequence clusters as a function of cluster radius. ​b​, Number of clusters for which models                 
predicted viable mutants at or above a minimum performance threshold. Cluster radius is at μ=12, the                
AAV natural serotype diversity within the target region. ​c​, Visualization of sampled diversity through ivis               
projections [34]. Purple: C​1​+R​10 ​training data (identical between panels). Dashed outline: area containing             
all model-designed sequences. Orange/blue/green: kernel density estimates for the viable capsid subset            
for LR/CNN/RNN models, respectively. Magenta: natural AAV serotypes (1-12) embedded for reference. 
 
 
While many machine learning studies are conducted on a single standardized dataset where only              
 
 
differences in model architecture choices are compared, our study highlights the value of optimizing              
training data distributions for improved predictive power. The fact that relatively small, simple, and              
unbiased training sets enable viability predictions far from wildtype suggests that similar approaches can              
be used for proteins in which high-throughput screens are impractical. Importantly, after such models              
have been trained, generating new sequences requires only additional compute time, bringing a vast              
number of diverse and functional synthetic variants within reach. This study lays the foundation for the                
efficient model-guided exploration of deep sequence space, empowering both basic biology and protein             
engineering. 
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AAV mutant sequence library generation and production assay 
Libraries were constructed using a method similar to that previously described in Ogden et al. [21]. For 
the final validation experiments, 184mer DNA oligonucleotides (oligos) were synthesized as 
single-stranded DNA by Agilent. Designed amino acid sequences were back-translated to nucleotide 
sequences by choosing any possible codon (generally keeping the WT codon and choosing mutant amino 
acid codons with no bias, but disallowing codon choices that created restriction enzyme sites used in 
cloning). From 5’ to 3’ each oligo contained: a forward primer binding site, a BbsI restriction site 
(5’-GAAGACAT|TACA-3’), an 84+ nucleotide mutant coding sequence, a BsaI restriction site 
(5’-CAAG|CGAGACC-3’), an EcoRV “kill cutter” restriction site, a BsaI restriction site in the opposite 
orientation (5’-GGTCTCA|CGCT-3’), an 18 nucleotide barcode sequence, a BbsI site in the opposite 
orientation (5’-CGCT|AAGTCTTC-3’), and a reverse primer binding site. Note that barcodes were 
included in the synthesized oligos but were not used for downstream sequencing or analysis (rather the 
mutant coding region was directly amplified and sequenced, matching the amplification method used in 
the prior production experiments). PyDNA[35] was used for in-silico testing of the cloning process, 
ensuring sequence compatibility with the cloning strategy. The code for executing this process is fully 
provided in the synthesis pipeline component of the bioinformatics pipeline code.  
 





Cloning was carried out in three steps. First, oligos were PCR amplified using Q5 high-fidelity DNA 
polymerase (NEB M0492) and an annealing temperature of 60°C (fwd: 5’-GGGTCACGCGTAGGA-3’, rev: 
5’-GTTCCGCAGCCACAC-3’). A backbone plasmid containing the WT AAV2 ​cap​ gene was also amplified 
with Q5 and an annealing temperature of 72°C (fwd: 
5’-TTGGTCTCA|CGCTAGAGACGGTGTGGCTGCGGAAC-3’, rev: 
5’-AAGGTCTCC|TGTAATCATGACCTTTTCAATGTCCACATTTG-3’). This PCR was used to add BsaI 
sites with overhangs complementary to the BbsI overhangs in the oligos (as indicated by cut sites in 
primer sequences). Amplified oligos were digested with BbsI-HF (NEB R3539) and amplified plasmid was 
digested with BsaIHF-v2 (NEB R3733) in separate 50 µL reactions. Digest products were purified using 
homemade SPRI beads, mixed at a 3:1 molar ratio (oligos: plasmid), and ligated using T4 DNA ligase (2 x 
10​6​ U/mL, NEB M0202). Ligation products were ethanol precipitated and transformed into 50 uL of 
electrocompetent cells (Lucigen 10G SUPREME 60081). Following a 1 hour recovery at 37°C, cells were 
added to 4 mL of selection media (2x YT with kanamycin) and grown at 37°C overnight. The following 
morning, step one library plasmids were mini-prepped by alkaline lysis (Qiagen 27104). In this first cloning 
step, oligo sequences replaced the corresponding 84 base pair WT sequence and the 3’ region of the ​cap 
gene in the backbone plasmid. 
 
In the second cloning step, an amplicon containing the 3’ WT region of the ​cap​ gene was generated from 




5’-AAGGTCTCA|AGCGAGAGACGTCCTACGCGTGACCC-3’). This amplification step was also used to 
add BsaI sites complementary to those in the oligos. Step one library plasmids and the 3’ WT amplicon 
were separately digested with BsaI-HFv2, bead purified, and ligated as above. Ligation products were 
digested with EcoRV-HF (NEB R3195) in a “kill cutting” step to remove step one plasmids that did not 
incorporate the 3’ WT amplicon. EcoRV digest products were ethanol precipitated, transformed, and 
mini-prepped as in step one. In the third cloning step, a destination ITR-containing plasmid was digested 
with HindIII-HF (NEB R3104) and SpeI-HF (NEB R3133). Complete mutant ​cap​ gene sequences were 
amplified from the step two plasmid library using Q5 and an annealing temperature of 70°C (fwd: 
3’-AGGTCTCA|AGCTTCGATCAACTACGCAGACAG-5’, rev: 
3’-AGGTCTCA|CTAGATGAGCTCGTCGACGTTCC-5’). This amplification step was also used to add 
BsaI sites and overhangs complementary to the HindIII and SpeI sites in the ITR plasmid. Amplicons 
were digested with BsaI-HFv2 as above. Digested ITR plasmid and step two library amplicons were bead 
purified, ligated, transformed, and mini-prepped to generate the final plasmid library. For the earlier 
rounds of library cloning, creation of mutant Cap genes were accomplished in a single cloning step, since 
oligos did not contain BsaI sites, EcoRV sites, or barcode sequences, enabling cloning directly into the 
corresponding position in the WT ​cap​ gene. Ligation sites and oligo and ​cap​ PCR primers for this single 
step cloning were the same as above. Similarly, the final library cloning step to move the mutant ​cap​ gene 
sequences into the ITR plasmid remained the same.  
 
The final plasmid library was transfected into HEK293T cells to produce viral particles. Cells were grown 
in DMEM (ThermoFisher 10566016) supplemented with 10% FBS (ThermoFisher 10082147) and seeded 
in 5-layer cell stacks (Corning 353144) two days prior to transfection. Polyethylenimine (PEI) was used for 
transfection at a mass ratio of 3:1; 125 ug of adenovirus pHelper plasmid, 75 ug of an AAV ​rep​ plasmid, 
and 1 ug of library plasmids were mixed with PEI, incubated for 20 minutes, and added to cells. Media 
was changed completely at the time of transfection and replicate transfections were carried out in 
separate cell stacks. Here, the lower levels of library plasmid were chosen to reduce the number of 
plasmids transfected into individual cells, such that potential for mosaic capsid formation and 
cross-packaging was minimized. Three days post-transfection, 5 M NaCl was added to the cultures for a 
final concentration of 0.5 M and cultures were incubated at 37°C for 3 hours. Following incubation, 
mixtures were transferred to fresh containers and incubated at 4°C overnight. The next day, the resulting 
supernatants were run through 0.22 µm PES filters (Corning 431098). 40% PEG-8000 was then added to 
a final concentration of 8% and mixtures were incubated at 4°C for 3 hours. Samples were centrifuged at 
3000 x ​g​ for 20 minutes to pellet the PEG precipitate and pellets were resuspended in 7 mL of DPBS. 
Viral genomes external to the capsid and carryover plasmid DNA were degraded with benzonase; a 
10,000-fold dilution of benzonase (Millipore Sigma ​1.01695.0001​) was added to resuspended pellets and 
samples were incubated at 37°C for 45 minutes. Encapsidated genomes were separated from the 
remaining cellular debris using iodixanol ultracentrifugation and concentration via size exclusion spin 
filters as described previously [21, 36]. Briefly, benzonase-treated samples were underlaid with an 
iodixanol gradient (Sigma D1556) in polypropylene tubes (Beckman Coulter 362183) and centrifuged at 
242,000 x​ g​ for 1 hour at 16°C. Capsids were collected from the 40% iodixanol fraction and concentrated 
using a spin concentrator (Millipore Sigma UFC910024) to generate the final purified pool. 
 
Cap​ gene sequences remaining in the purified pool represent mutants viable for capsid assembly and 
genome packaging. Purified capsids were heat denatured at 98°C for 10 minutes and PCR was run with 
Q5 and an annealing temperature of 65°C to amplify the mutant region of the ​cap​ gene (fwd: 
 
 
5’-​GCTCAGAGAAAACAAATGTGGAC​-3’, rev: 5’-​GAACGCCTTGTGTGTTGACATC​-3’). PCR reactions 
were carried out in the presence of EvaGreen (Biotium 31000) and run on a BioRad CFX96 qPCR 
machine to ensure that reactions were stopped during the exponential phase. Illumina sequencing 
adapters and indices were added in a subsequent PCR. These PCR amplicons were sequenced with 
overlapping paired end reads using an Illumina NextSeq. Paired-end reads were merged to generate a 
consensus read using PEAR [37], and read counts were calculated for every member of the designed 
library.  Reads with a minimum Q score of 20 were selected for four technical plasmid replicates and 
three biological virus replicates (each with at least 2 technical replicates, Supplementary Fig 2). Mutant 
fitness in the viral production assay was calculated by taking the ratio of mutant read counts in the viral 
library over the counts in the original DNA library, normalizing by the ratio of the WT sequence. 
 
Measurement of viral genome abundances from tissues for the design of the A39 data set was done via 
amplicon sequencing from purified vector genomes, with PCR protocols as described above. Three 
separate batches of virus were prepared and 3.5e10vg (batch 1), 2.3e10vg (batch 2) and 3.5e10vg (batch 
3) of the C​1​ virus library was diluted in 200uL PBS and injected into a mouse, 4 mice per batch, for 12 
mice in total. Mice were all 8 weeks old, male, and C57BL/6J. For each of the 3 batches, 2 mice were 
injected retro-orbitally and 2 intraperitoneally. 30uL blood was drawn after 1 hour, 5 hours and 24 hours 
by facial bleed from and frozen on dry ice, then at -80C. After 8 days, mice were dissected and tissue 
samples from liver, kidney, heart, lung, brain, spleen, muscle, skin, stomach, and testes were frozen on 
dry ice, then at -80C. Approximately 150 mg of each organ was ground using disposable mortar and 
pestle (Kimble Chase 749625-0010). DNA was purified from tissues using alkaline lysis (Qiagen 27104) 
and from blood using Qiagen MinElute Virus Spin Kit (57704). Biodistribution was similar across both 
routes of administration. The overall effect on biodistribution of viral genomes for each organ and blood 
sample was calculated in R using deseq2 across measurements from multiple mice: combining 12 mice 
for blood and liver, and 4 mice from batch 2 for the remainder of organs. 
 
Random sampling of AAV2 mutants around wildtype 
To generate a sequence at mutation distance ​k​ steps from WT AAV2, first a uniform random draw from 
the set of {28 WT positions + 28 insertion positions} was made. This mutation was then removed from the 
consideration set; and ​k​-1 subsequent draws without replacement from the remaining set of unsampled 
positions were then made until ​k​ distinct mutation positions were selected. For each of the ​k​ positions 
selected, a residue type was selected uniformly at random: for insertion positions, all 20 standard amino 
acids were available; for substitution positions the 19 amino acids distinct from WT were available. The 
set of ​k​ mutations relative to the WT AAV2 sequence then fully defines a mutant sequence at distance ​k 
from WT. 
 
Baseline random sequence set generation 
The train (7908 variants) + tune (1977 variants) random multi-mutant sequence set was generated by 
sampling 1732-1756 sequences at each distance of 2-6 steps away from WT, inclusive, and 288-290 
sequences from 7-10 steps, inclusive. In total, the random multi-mutant sequence baseline experiment 
tested 9885 unique sequences between 2-10 steps, inclusive. 
 
Baseline additive model sequence set generation 
The biodistribution of the C​1​ library across liver, kidney, heart, lung, brain, spleen, muscle, skin, stomach, 
testes, and blood samples was used to compute selection scores (the relative enrichment of variants in 
 
 
the tissue vs. the original plasmid library) for each sample. This data all contained information about 
production ability, as viral production is a necessary requirement for viruses to be observed in each 
tissue, and was therefore a common contributor to variance across all models. We generated mutants for 
the A​39​ set using data from biodistribution data rather than simply production data so as to facilitate 
enrichment of variants with diverse biodistribution phenotypes within the additive set--however we 
focused on training ML models using the production assay measurements because these higher accuracy 
measurements enabled us to better assess the predictive power of our models during the final round of 
validation experiments. 
 
We generated random mutants in three ways: i) allowing substitutions across the region, ii) allowing 
substitutions and insertions (but no more than one amino-acid between two positions) and iii) allowing 
substitutions but restricting the same insertions to the second half of the tile.  
 
To design variants from single mutants data with the additive model, we employed three flavors of Monte 
Carlo sampling, as follows:  
1. For each position along the region of interest, we constructed a Boltzmann distribution defined as 
,  where  was the tropism for amino-acid ​i​ in that position as measured in the singles/Z2s /T  i si  
library (for different tissues) and ​Z​ ensured that the sum of probabilities across the position 
equaled 1. The temperature parameter T, controlled the degree of fidelity to the best proposed 
mutation according to the additive model, with higher T resulting in more diverse choices but 
lower expected fitness gain.  We then combined mutations by scanning across the region of 
interest and sampling amino-acids probabilistically for each position (potentially WT). The 
parameter T was fixed during the generation of each variant. However to produce a diverse 
library we varied T between 10​[-2, 0]​ (with 0.18 increments in the exponent) for different variants. 
The A​39​ dataset contains 18,155 unique sequence variants generated using this process. 
2. For each position along the region of interest, we sampled uniformly from a subset of amino-acids 
that had selective advantage above threshold .  ​We varied the between [-1, 2] to inducets ts  
further variation.  The A​39​ dataset contains 23,420 unique sequence variants generated using this 
process. 
3. For each variant, we would randomly sample multiple single edits, and only accept the variant if 
the sum of effects from the individual mutations were above the threshold . We varied tm tm
between [0, 2.33] to induce variation.  The A​39​ dataset contains 14,797 unique sequence variants 
generated using this process. 
 
For variants with multiple mutations against WT reference, we would sometimes also sample related 
variants by introducing the mutations included in the variant one at a time. The order in which these 
mutations were introduced was either greedy (meaning better mutations introduced first) or at random. 
Hence these sets of mutations would entail a stepwise “path” from WT to the target variant. Additionally, 
we sampled around 11,000 unique variants randomly.  
 
Construction of ML training datasets ​ ​C​1​+R​2​, C​1​+R​10​ and R​10​+A​39 
Our experimental design compares three libraries of training data that each contain different numbers of 
sequence variants that were sampled from a constrained interval of sequence space around the wildtype 
AAV2 sequence using three distinct sampling strategies. The additive dataset (A​39​) provides a baseline 
training data set in which mutants were generated first by measuring the complete set of single mutants 
 
 
and then generating diverse mutants using additive models (see section above). In contrast, the other two 
libraries (R​2​ and R​10​) exploit the power of random sampling to choose sequences with multiple mutations 
sampled uniformly at random from the sequence space around the wildtype sequence, and are more 
efficient in that they require only one experiment to generate training data. 
 
The C​1​+R​2 ​dataset (N=2,868, 40% viable) contains: (i) the complete set of single site mutants, C​1 
(N=1,112, 58% viable); and (ii) a <1% random subset of the possible double mutants, R​2​ (N=1,756, 29% 
viable). The types of single mutants allowed in this study included all possible substitutions at the 28 
residue positions considered and all possible single-residue insertions between and surrounding the 28 
positions; i.e., 29 possible insertion positions, resulting in 29*20 (insertions) + 28*19 (non-WT 
substitutions) = 1,112 single site mutants.  
 
The C​1​+R​10​ dataset (N=9,020, 16% viable) contains: (i) the complete set of single site mutants, C​1 
(N=1,112, 58% viable); and (ii) a set of 7,908 randomly generated mutants with 2-10 mutations (10% 
viable). Note that the randomly generated mutants are fully disjoint from the validation set discussed in 
the ML model training Methods section. While many of the 7,908 randomly generated mutants are 
non-viable, these negative examples still provided valuable information about the sequence space to aid 
ML models during training.  
 
The R​10​+A​39 ​dataset (N=64,280, 56% viable) contains: (i) A​39​, the 56,372 mutants generated by the 
baseline additive single site fitness model described in Methods, (62% viable); and (ii) R​10​, the same 
7,908 sequences with 2-10 randomly generated mutants as the C​1​+R​10 ​dataset (10% viable). Note that 
the R​10​+A​39 ​dataset does not contain the 1,112 single site mutants (C​1​). The comparison between C​1​+R​10 
and R​10​+A​39​ explicitly tests the effect of training on a dataset that explicitly includes all the single mutant 
variants, vs a dataset that includes a large number of higher order variants designed using the single 
variant data, and tested in an additional round of data collection experiments. 
 
Across all three libraries of training data, for each sequence variant we required a plasmid count > 100 to 
provide some insulation from noisy mutant fitness measurements caused by low plasmid counts for 
specific variants. The resulting dataset contained at least four synonymous nucleotide sequences for 
each amino acid sequence variant present, and for each unique amino acid sequence present we took 
the highest observed fitness measurement across the synonymous nucleotide sequences that each had 
plasmid count > 100.  
 
ML model experimental design overview 
We use all three datasets to train classification models that predict whether a distant variant of the AAV2 
capsid sequence is functional, as illustrated in Fig 1b. To provide a baseline approach in which 
interactions between different mutations are not captured by the learned model, we trained logistic 
regression models. Although these models are restrained by their inability to capture higher order 
interactions, they have the advantage that the number of free parameters is comparatively small, 
potentially avoiding the issue of overfitting that might temper the predictive ability of more complex 
models, in particular when trained using the smaller of our three training libraries. In addition, we also 
trained both convolutional and recurrent neural network models using each of the three datasets. The 
CNN architecture was selected to assess the value of providing contiguous windows of local mutations as 
raw feature inputs to a deep NN, allowing it to assemble small local windows into larger aggregated 
 
 
receptive fields at deeper layers of the model. The RNN architecture was selected to assess the utility of 
having a stateful deep NN with aggregated knowledge of the mutations incorporated N-terminal to a given 
mutation; specifically, a unidirectional, multi-layered LSTM architecture was used.  For all model 
architectures we used a simple one-hot representation of the input sequence data, and supervised the 
model using binary labels for packaging, derived from the experimental measurements after taking into 
account the experimental noise present in the assay (see Supplementary Fig 1).  
 
Training ML models 
Our cross product of three model architectures (LR, CNN, RNN) and three distinct training datasets 
(C​1​+R​2​, C​1​+R​10​, R​10​+A​39​) resulted in nine categories of trained machine learning models (LR{C​1​+R​2​}, 
LR{C​1​+R​10​}, ..., RNN{R​10​+A​39​}). Within each (architecture, dataset) category, we trained 11 replica 
models, using distinct random initializations, to yield an ensemble model. Replica performance, 
specifically classification precision as a function of distance from WT, on a held out random mutant 
validation set was used for terminating training via early stopping for each replica. To evaluate a given 
sequence, the mean model replica score of the ensemble was used; these 11-replica mean model scores 
were used for ranking sequences generated by both the model-based selection and model-guided design 
approaches.  
 
The CNN and RNN were optimized using the Adam algorithm (with learning rates of 0.001 and 0.01, 
respectively) while the TensorFlow logistic regression implementation utilized the FTRL algorithm with a 
learning rate of 0.01.  The learning rates were selected via a hyperparameter sweep - selecting the 
learning rate with the best validation performance on the ​C​1​+R​10​ training set for each model. ​All models 
were trained using a binary softmax cross entropy loss.  
 
Models were regularized via early stopping using the implementation provided within 
`train_utils.EarlyStopper`. Model training progression was monitored using the hold-out validation set of 
sequences that was the same for every architecture. Early stopping halted training after the model's 
precision on the validation set did not increase for 10 evaluation periods. An evaluation period occurs 
every 500 steps in our setup, with a batch size of 25 examples per step.  The mean and max wall-times 
were 20.3, and 85.3 minutes, respectively. 
 
Architecture selection and hyperparameter tuning for neural network models 
The complexity of the architectures tested varied from the simplest logistic regression (LR) model with 
only 1,161 params and 0 hidden layers, to the CNN model with 55,189 params and 4 hidden layers 
{ConvPool, ConvPool, FC, FC} and finally to the most complex RNN (LSTM) model with 128,901 params 
and 2 hidden layers {FC, FC}.​ ​All hyperparameter tuning was done while training on the fully random 
C​1​+R​10 ​dataset (N=9,020) and evaluating against a single validation set comprised of randomly sampled 
2-10x mutant sequences (N=1,977); the validation set was also used for early stopping of training. Note 
that this validation set is fully disjoint from the random 2-10x mutant set incorporated into the R​10​ dataset. 
 
The Convolutional Neural Network (CNN) model​ ​uses​ ​55,189 params and 4 hidden layers: 
● Input shape: (58, 20) 
● Conv1d-relu-BN<width=7, depth=12> 
● Pool1d<width=2, stride=2> 
● Conv1d-relu-BN<width=7, depth=24> 






The Recurrent Neural Network (RNN) model, a multilayer LSTM, uses 128,901 params with 2 hidden 
layers, each having 100 units: 
● Input token shape: (20) 
● LSTM cell layer 1 (100 units) 
● LSTM cell layer 2 (100 units) 
 
Retrospective model validation 
Before using the trained ML model ensembles to propose new diverse sequence variants predicted to be 
viable, we used the baseline additive set of 56,372 multi-mutant variants (A​39​) as a held out test set with 
which to compare the models trained using either the C​1​+R​2​ or C​1​+R​10 ​dataset, both of which excluded the 
A​39​ set of sequences. We were surprised to find that while all models exhibited a degree of lift in their 
ability to accurately predict viable mutants far from WT, compared to the additive model used to select the 
baseline set, the performance of the NN models trained using the 3x larger C​1​+R​10 ​dataset (N=9,020) was 
comparable to that obtained using the smaller C​1​+R​2​ dataset (N=2,868), which only included single and 
double mutants. We note that while the R​2​ and R​10​ datasets are randomly generated, they contain 
multiple examples of sequence variants for which the measured phenotype does not reflect an additive 
model given the C​1​ data. These cases are more difficult for the LR model to fit, providing a potential 
explanation for this performance difference compared to the NN models.  
 
Generating sequences via ML model-based selection 
The pool of AAV2 mutant sequences from which ML models were allowed to rank and select was created 
by randomly sampling sequences 100 million times for each mutation distance between 5-25, inclusive, 
thereby generating a total of 2.1 billion candidate sequences as shown in Fig 1c. To randomly sample a 
sequence at distance ​n​ from wildtype, ​n​ indices between [0, 58) (2 * the number of positions in tile21) 
were drawn at random (note, prefix insertions were not permitted).  For each index a random 
non-wild-type amino acid residue was selected (for indices corresponding to insertion positions any 
residue was permitted). Each of the ML models compared in this work was then used to evaluate the 
entire pool of 2.1 billion sequences, selecting the top 1,000 sequences at each mutation distance. These 
top 1,000 sequences at each mutation distance were then used as "seed" sequences for the 
model-guided sequence design process described below. The top 100 of the 1,000 seed sequences at 
each distance from wildtype were also tested empirically for viability (before any model-guided sequence 
design); the performance of these top 100 sets are shown in Fig 2 for each model, and are referred to as 
the model-based selection set throughout this work. 
 
Generating sequences via ML model-guided design 
To go beyond model-based selection, we developed a model-guided sequence design strategy to follow 
model gradients and find sequences with higher scores. Our previous experiment suggests that roughly 
3k of the 100 Million random candidates 15 steps from WT will be viable, diminishing to just 100 of those 
20 steps from WT. This is supported by a marked decrease in model confidence for sequences that are 
far from WT. We next asked whether the trained models could utilize their internal representation of the 
AAV2 fitness landscape to “evolve” seed sequences in promising directions by exploring local 
neighborhoods around randomly sampled candidate sequences that the model predicts to be viable. The 
 
 
1,000 highest scoring sequences at each distance from WT were selected by ML models (specifically in 
each case by an ensemble of 11 replica models with the same architecture, trained on the same training 
data) as ​seed​ sequences (with the top 100 at each distance experimentally evaluated).  
 
Starting from these model-selected seed sequence variants we performed an iterative mutation process. 
First, a random set of 250 single mutation steps (disallowing movements towards WT) were scored using 
the model ensemble mean probability (see Training ML Models).  The highest-scoring 50 candidates were 
passed forward for the next iteration of mutation. We terminated this process after 20 iterations because 
the resulting variants exceeded the most distant viable sequence variant discovered by the additive 
baseline strategy (21 steps from WT). After 20 iterations were completed, the total set of evaluated 
sequences across all mutation levels was ranked by consensus score. This model-ranked set was 
greedily filtered for diversity, only permitting the addition of a candidate sequence if it was at least 3 
mutations away from a higher scoring sequence already included in the set. These candidate sets were 
aggregated across all model-selected seed sequences, with the top 900 sequences at each distance 
between 5-25, and the top 500 sequences at distances 26-29 selected.  As most model-designed, viable 
sequences originated from viable seeds (Supplementary Fig 5), viable sequences even further from 
wild-type may be possible by increasing the number of iterative mutation rounds. 
 
Prospective model validation 
To truly test the hypothesis that a small amount of double mutant data is enough to significantly improve 
the models over the additive model trained using all single site variants, we experimentally validated 
sequences proposed using multiple training strategies. This framework has the advantage that it also 
allows the randomly chosen training libraries to be compared with the much larger set of sequences 
designed using the simple additive model, as an alternative information-rich training dataset.  
 
The model selected and model designed sequences were labelled viable or non-viable by calculating the 
ratio of mutant read counts in the viral library over the counts in the plasmid DNA library, and comparing 
to this ratio calculated for the WT sequence. To confirm that our results were robust to noise due to small 
absolute counts, we excluded sequence variants with <10 plasmid counts from the reported results. Note 
that this threshold is more permissive than that used for the training data, reflecting our desire to avoid 
training the models on data with noisy labels. Furthermore, we confirmed that the reported trends in terms 
of the performance as a function of distance from the WT sequence, and the diversity of model designed 
sequences were maintained if in addition we imposed more stringent criteria. We first restricted to those 
sequences for which the viral counts from each of the three biological replicates agree that the sequence 
is either viable or non-viable. This dataset yielded ​100,929 viable sequences out of 172,664 model 
designed sequences that met this criteria. ​In a second analysis, we removed the 2,055 viable sequences 
that had <50 viral counts, and verified that the reported trends still hold using this slightly smaller set of 
viable sequences.  
 
A surprising outcome of this experiment was that although the R​10​+A​39 ​dataset contained 5x and 25x more 
sequences than the C​1​+R​10​ and C​1​+R​2​ datasets, respectively, this abundance of training data did not 
always improve its ability to accurately identify viable sequences. In particular, the LR and RNN models 
trained using the R​10​+A​39​ dataset were outperformed by their respective variants trained using the smaller 
C​1​+R​10 ​dataset, and in the RNN case also by the C​1​+R​2​ dataset. Only in the case of the CNN did the 
larger R​10​+A​39​ training set result in a significant improvement in performance, in particular in the ability to 
 
 
identify sequences that were further away from wildtype.  
 
As a post-hoc observation, across all models we empirically observed a decline in performance above 18 
steps from WT. Since Fig 2a shows that the model-selected seeds become significantly less likely to be 
viable around 8-12 steps from WT, this decline is at least partly explained by the choice of a 20-iteration 
maximum model-design iterations mentioned above.  
 
Sequence clustering 
To cluster each set of model designed sequences, we first sorted them in descending order by the 
number of mutations from WT AAV2 (i.e. farthest first). For a given cluster radius, ​R​, we start with the first 
sequence in the list and use it as a founder, then build a cluster around it by including every as-yet 
unclustered sequence <​R​ edit distance from the founder sequence. We then repeat this process with the 
next remaining farthest-from-WT sequence in the yet-to-be-clustered set, and so forth, until all sequences 
have been placed into clusters.  
 
Each set of designed sequences was of a different cardinality (e.g., 2.5x additive sequences versus 
ML-designed sequences), and to make the sets comparable as presented in Fig 4a,b, we downsampled 
all sequence sets uniformly at random to the smallest common size: 19,680 sequences. We then 
clustered the viable subset of these partitions to present in Fig 4, which quantifies the volume of 
sequence space successfully covered for various clustering radii.  To provide an additional perspective, 
we separately clustered all of the downsampled sequences (viable + non-viable) for the statistics 
presented in Fig 4b, which quantifies the volume of sequence space covered versus capsid design 
success rates (% viable) at a fixed radius of 12 (μ AAV serotype diversity). 
 
AAV2 homolog selection and alignment construction 
In order to compare our diversification approach with natural diversity, we investigated the available 
sequences on NCBI for dependoparvoviruses. We  found 415 complete coding sequence records (~1000 
gene products) for dependoparvoviruses (txid 10803) which contained a structural or VP protein. This 
data was parsed to extract structural and VP1 proteins. Records without a complete structural or VP 
protein were discarded. We also ensured that we included all common AAV VP1 sequences (12 
sequences).  This processing results in 310 unique sequences which we aligned using ClustalW ​[​38​]​. We 
then extracted the corresponding sequence to AAV2 VP1 region of interest for each record to compute 
the statistics for natural diversity. We found that for the 28-amino acid region of interest, the 
dependoviruses show slightly ​less ​diversity than the common 12 serotypes (i.e. a lot of sequences are 
quite similar to each other, and AAV2). Therefore, for comparisons in the paper, we used the common 12 







Supplementary Figure 1 | ​Bimodal packaging viral selection coefficient distribution. a​, Viral            
selection coefficients for 168 sequences known to produce successfully (WT AAV2 alternate codon             
variants) and 162 sequences known to fail at production (capsid variants truncated via stop codon               
insertions) from the initial experiment. The viral selection threshold for the viable/non-viable classes was              
determined by fitting the 2-component GMM shown (red and purple lines), on a log2 scale. ​b​, ​Viral                 
selection coefficients for 200 sequences known to produce successfully (WT AAV2 alternate codon             
variants) and 171 sequences known to fail at production (capsid variants truncated via stop codon               
insertions) from the final experiment. ​c, d Distributions of all >70k variants from the initial experiment and                 
all >240k variants from the final experiment are bimodal, motivating our use of categorical prediction               
models. These distributions illustrate the binary nature of the packaging assay outcomes and the intrinsic               






Supplementary Figure 2 | Reproducibility within and across experiments,​ ​a​, Pearson correlation 
between plasmid replicates and virus replicates in ML validation set. For each of the four biologically 
replicated virus experiment (numbered), we have at least two technical (PCR) replicates (denoted by 
letters). ​b​, We replicated the measurements for 2000 unique samples with a range of selection scores 
from our ML training data as control on the validation chip designed by the classifiers to calibrate our 
comparison with the additive model and ensure reproducibility of results.  
 
 
Supplementary Figure 3 | Comparison of individual and ensemble model performance.​ Evaluation 
of the performance of both the single (black dots) and ensemble (pink triangles) models built for each 
architecture/training set combination using the area under the receiver operating characteristic (AUROC). 
For the ensemble, we average the scores of each eleven individual models before computing the 
AUROC. Overall we find that the ensembles consistently outperform the median performance of individual 
models, in some cases outperforming the best individual model as well. Note that logistic regression 
replicate models tend to display highly similar performance regardless of initialization, while the effects of 
random initializations can be quite significant for the neural networks. As a result, the performance gain 






Supplementary Figure 4 | (a) Mutation preference distribution for all ML models. ​Heatmaps showing 
counts of substitutions (top) and insertions (bottom) within viable mutant capsids with ≥12 mutations as 







Supplementary Figure 4 | (b)​ ​Logos showing viable model-designed sequences for ML models 
trained on the C​1​ + R​10​ dataset. ​Sequence logos showing amino acid usage within viable mutant capsids 
with ≥12 mutations from the AAV2 wildtype sequence as designed by each model architecture (LR, CNN, 











Supplementary Figure 4 | (c)​ ​Logos showing viable model-designed sequences for ML models 
trained on the R​10​ + A​39​ dataset. ​Sequence logos showing amino acid usage within viable mutant 
capsids with ≥12 mutations from the AAV2 wildtype sequence as designed by each model architecture 











Supplementary Figure 4 | (d)​ ​Logos showing viable model-designed sequences for ML models 
trained on the C​1​ + R​2​ dataset. ​Sequence logos showing amino acid usage within viable mutant capsids 
with ≥12 mutations from the AAV2 wildtype sequence as designed by each model architecture (LR, CNN, 





Supplementary Figure 5 | Relationship between model-designed sequences and their 
model-selected starting seeds. a, ​The set of model-designed sequences with experimentally tested 
seeds are shown within each facet.  Model-designed sequences for a particular seed are rendered at the 
same x-axis position and colored by whether they were <18 (blue) or >=18 (orange) mutations from 
wildtype. The seeds are sorted by their viral selection value (y-axis). The horizontal blue line corresponds 
 
 
to the viability cutoff.  Most models show a strong preference for viable model-designed sequences from 
viable seeds.  ​b,  ​The relative fraction of viable (blue) and non-viable (red) model-designed sequences 
that came from viable seeds (dark alpha) and non-viable seeds (light alpha).  Most models start from 
viable seeds and identify viable children close to WT. Far from WT, models become less reliable and 
more likely to start from non-viable seeds.that came from viable seeds (dark alpha) and non-viable seeds 
(light alpha).  Most models start from viable seeds and identify viable children close to WT. Far from WT, 






Supplementary Table 1 | ML-generated AAV2 capsid statistics by mutation count.​ Cumulative viable 
capsid generation statistics across all machine learning models (LR, CNN and RNN), including both 
model-designed and model-selected sequences across all training datasets (C​1​+R​2​, C​1​+R​10​, and R​10​+A​39​), 
for a range of mutations-from-WT thresholds. The bolded row corresponds to the mutation distance at 












2 201,426 110,689 55.00% 62.50% 
3 201,426 110,689 55.00% 59.50% 
4 201,424 110,687 55.00% 53.70% 
5 201,368 110,633 54.90% 46.10% 
6 193,413 103,403 53.50% 36.40% 
7 184,424 95,422 51.70% 21.30% 
8 175,443 87,571 49.90% 17.30% 
9 166,361 79,628 47.90% 13.70% 
10 157,294 72,180 45.90% 10.70% 
11 148,167 64,678 43.70% 8.30% 
12 138,815 57,348 41.30% 6.30% 
13 129,433 50,330 38.90% 4.70% 
14 119,469 43,236 36.20% 3.50% 
15 109,474 36,173 33.00% 2.40% 
16 99,137 29,326 29.60% 1.60% 
17 88,694 22,901 25.80% 1.00% 
18 78,951 17,588 22.30% 0.60% 
19 69,612 13,233 19.00% 0.40% 
20 60,049 9,710 16.20% 0.30% 
21 51,164 7,048 13.80% 0.10% 
22 42,202 4,952 11.70% 0.00% 
23 33,500 3,301 9.90% 0.00% 
24 24,879 1,983 8.00% 0.00% 
25 16,977 1,038 6.10% 0.00% 
26 11,089 484 4.40% 0.00% 
27 7,350 196 2.70% 0.00% 
28 4,094 52 1.30% 0.00% 





Supplementary Table 2 | ML-designed AAV2 capsid statistics by mutation count.​ Cumulative viable 
capsid generation statistics across all machine learning models (LR, CNN and RNN), for only 
model-designed sequences (i.e., excludes model-selected) across all training datasets (C​1​+R​2​, C​1​+R​10​, 
and R​10​+A​39​). The bolded row corresponds to the mutation distance at which the models first exceed the 












2 183,466 106,665 58.10% 62.50% 
3 183,466 106,665 58.10% 59.50% 
4 183,464 106,663 58.10% 53.70% 
5 183,411 106,612 58.10% 46.10% 
6 176,351 100,150 56.80% 36.40% 
7 168,231 92,923 55.20% 21.30% 
8 160,096 85,766 53.60% 17.30% 
9 151,805 78,411 51.70% 13.70% 
10 143,464 71,416 49.80% 10.70% 
11 135,099 64,267 47.60% 8.30% 
12 126,589 57,157 45.20% 6.30% 
13 118,046 50,243 42.60% 4.70% 
14 108,965 43,188 39.60% 3.50% 
15 99,868 36,138 36.20% 2.40% 
16 90,448 29,299 32.40% 1.60% 
17 80,932 22,879 28.30% 1.00% 
18 72,082 17,571 24.40% 0.60% 
19 63,657 13,217 20.80% 0.40% 
20 55,026 9,698 17.60% 0.30% 
21 47,032 7,039 15.00% 0.10% 
22 38,986 4,946 12.70% 0.00% 
23 31,190 3,297 10.60% 0.00% 
24 23,441 1,980 8.40% 0.00% 
25 16,395 1,037 6.30% 0.00% 
26 11,089 484 4.40% 0.00% 
27 7,350 196 2.70% 0.00% 
28 4,094 52 1.30% 0.00% 





Supplementary Table 3 | NN-designed AAV2 capsid statistics by mutation count.​ Cumulative viable  
capsid generation statistics across all neural network models (CNN and RNN) for only model-designed 
sequences across all training datasets (C​1​+R​2​, C​1​+R​10​, and R​10​+A​39​) for a range of mutations-from-WT 
thresholds (i.e., excludes model-selected sequences).  The bolded row corresponds to the mutation 












2 123,331 79,837 64.70% 62.50% 
3 123,331 79,837 64.70% 59.50% 
4 123,329 79,835 64.70% 53.70% 
5 123,280 79,788 64.70% 46.10% 
6 117,855 74,431 63.20% 36.40% 
7 112,376 69,020 61.40% 21.30% 
8 106,907 63,624 59.50% 17.30% 
9 101,326 58,145 57.40% 13.70% 
10 95,698 52,658 55.00% 10.70% 
11 90,035 47,192 52.40% 8.30% 
12 84,291 41,688 49.50% 6.30% 
13 78,449 36,219 46.20% 4.70% 
14 72,332 30,635 42.40% 3.50% 
15 65,960 24,953 37.80% 2.40% 
16 59,277 19,247 32.50% 1.60% 
17 52,702 13,997 26.60% 1.00% 
18 46,774 9,856 21.10% 0.60% 
19 41,028 6,559 16.00% 0.40% 
20 35,300 4,092 11.60% 0.30% 
21 30,053 2,482 8.30% 0.10% 
22 24,771 1,385 5.60% 0.00% 
23 19,712 670 3.40% 0.00% 
24 15,145 338 2.20% 0.00% 
25 10,854 165 1.50% 0.00% 
26 7,306 72 1.00% 0.00% 
27 4,887 47 1.00% 0.00% 
28 2,666 15 0.60% 0.00% 
 
 
29 942 4 0.40% 0.00% 
 
 
Supplementary Table 4 | Model-selected AAV2 capsid statistics per ML model. 
Model # Generated Capsids # Viable Capsids % Viable Capsids 
LR{C​1​+R​2​} 2,071 114 5.5% 
LR{C​1​+R​10​} 1,989 486 24.4% 
LR{R​10​+A​39​} 2,030 340 16.7% 
CNN{C​1​+R​2​} 2,022 381 18.8% 
CNN{C​1​+R​10​} 1,924 476 24.7% 
CNN{R​10​+A​39​} 1,898 529 27.9% 
RNN{C​1​+R​2​} 2,045 575 28.1% 
RNN{C​1​+R​10​} 1,916 412 21.5% 
RNN{R​10​+A​39​} 2,065 711 34.4% 
 
 
Supplementary Table 5 | Model-designed AAV2 capsid statistics per ML model. 
Model # Generated Capsids # Viable Capsids % Viable Capsids 
LR{C​1​+R​2​} 19,999 1,483 7.4% 
LR{C​1​+R​10​} 20,456 19,211 93.9% 
LR{R​10​+A​39​} 19,680 6,134 31.2% 
CNN{C​1​+R​2​} 20,454 11,229 54.9% 
CNN{C​1​+R​10​} 20,395 13,086 64.2% 
CNN{R​10​+A​39​} 20,759 14,968 72.1% 
RNN{C​1​+R​2​} 20,154 13,056 64.8% 
RNN{C​1​+R​10​} 20,838 15,525 74.5% 






Supplementary Table 6 | Additive model (A​39​) capsid statistics.​ Cumulative across edit distance 
thresholds. 
Min Mutations Threshold # Generated Capsids # Viable Capsids % Viable Capsids 
2 56,372 35,217 62.5% 
3 50,572 30,068 59.5% 
4 41,232 22,129 53.7% 
5 31,561 14,551 46.1% 
6 22,407 8,159 36.4% 
7 13,892 2,953 21.3% 
8 12,603 2,181 17.3% 
9 11,387 1,561 13.7% 
10 10,245 1,101 10.7% 
11 9,171 757 8.3% 
12 8,160 511 6.3% 
13 7,195 340 4.7% 
14 6,312 224 3.5% 
15 5,495 134 2.4% 
16 4,757 74 1.6% 
17 4,102 42 1.0% 
18 3,522 22 0.6% 
19 2,994 13 0.4% 
20 2,541 8 0.3% 
21 2,148 2 0.1% 
22 1,790 0 0.0% 
... ... ... ... 
37 30 0 0.0% 
38 16 0 0.0% 






Supplementary Table 7 | Randomly generated (R​10​) capsid statistics.​ Cumulative across edit distance 
thresholds. 
Min Mutations Threshold # Generated Capsids # Viable Capsids % Viable Capsids 
2 9,885 964 9.80% 
3 8,129 461 5.70% 
4 6,378 213 3.30% 
5 4,631 93 2.00% 
6 2,883 32 1.10% 
7 1,154 3 0.30% 
8 866 2 0.20% 
9 576 1 0.20% 
10 284 1 0.40% 
 
 
 
 
 
 
